Barclays increases target price of Integra Lifesciences stock to $70 — 4 quick facts

Integra Lifesciences stock had its price target increased by Barclays from $63 to $70 in a research report sent on May 29, according to a Dakota Financial News report.

Advertisement

Here are four quick facts:

 

1. Integra Lifesciences has a 52-week low of $44.11 and a 52-week high of $69.03.

 

2. The stock’s 50-day moving average is $63 and its 200-day moving average is $57.

 

3. The company has a market cap of $2.23 billion.

 

4. On average, the company has a rating of ‘buy’ and an average price target of $69.

 

More articles on devices:
MIS SI joint fusions: 5 key notes on the NASS coverage recommendation
Materialise partners with Consensus Orthopedics — 4 things to know
Mazor Robotics gets “buy” rating — 6 quick updates

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • From new technology acquisitions to regulatory clearances to leadership changes, here are 20 developments and updates from the biggest players…

  • VB Spine has made big pushes into the spine medtech space so far in 2026, including global expansions. Six headlines…

Advertisement

Comments are closed.